← All trials
NCT04495257
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2020
- Primary completion
- Aug 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Jul 31, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yale UniversityLead sponsor
- Yale UniversityOverall official - principal investigator
- Yale UniversityReponsible party - principal investigator
- Apexigen, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.